Danielle Santana Mello

Danielle Santana Mello

Auto-generated profile, based on publicly available information

Danielle Santana Mello

Department of Dermatology, Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
PDF file
CSClaudia Giuli Santi
Claudia Giuli Santi
AGAlexandre Carlos Gripp
Alexandre Carlos Gripp
ARAna Maria Roselino
Ana Maria Roselino
DMDanielle Santana Mello
Danielle Santana Mello
JGJuliana Olivieri Gordilho
Juliana Olivieri Gordilho
APAdriana Maria Porro
Adriana Maria Porro
Bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita are subepidermal autoimmune blistering diseases whose antigenic target is located at the basement membrane zone. Mucous membrane pemphigoid and epidermolysis bullosa acquisita can evolve with cicatricial mucosal involvement, leading to respiratory, ocular and/or digestive sequelae with important morbidity. For each of these dermatoses, a literature review covering all therapeutic options was performed. A flowchart, based on the experience and joint discussion among the authors of this consensus, was constructed to provide treatment orientation for these diseases in Brazil. In summary, in the localized, low-risk or non-severe forms, drugs that have immunomodulatory action such as dapsone, doxycycline among others may be a therapeutic option. Topical treatment with corticosteroids or immunomodulators may also be used. Systemic corticosteroid therapy continues to be the treatment of choice for severe forms, especially those involving ocular, laryngeal-pharyngeal and/or esophageal mucosal involvement, as may occur in mucous membrane pemphigoid and epidermolysis bullosa acquisita. Several immunosuppressants are used as adjuvant alternatives. In severe and recalcitrant cases, intravenous immunoglobulin is an alternative that, while expensive, may be used. Immunobiological drugs such as rituximab are promising drugs in this area. Omalizumab has been used in bullous pemphigoid.

1 December 2018 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
PDF file
DMDanielle Santana Mello
Danielle Santana Mello
MFMariana Rita de Novaes Fernandes
Mariana Rita de Novaes Fernandes
AGAlexandre Carlos Gripp
Alexandre Carlos Gripp
MAMaria de Fátima Guimarães Scotelaro Alves
Maria de Fátima Guimarães Scotelaro Alves
Granuloma annulare is a relatively common, idiopathic, benign inflammatory dermatosis, with a varied clinical presentation that often makes diagnosis difficult. It mainly affects the extremities, such as the dorsa of the hands and feet, forearms and legs. Palmar and plantar regions are generally spared. It occurs mainly in young female patients. The presentation of the palmar variant in an elderly patient is a rarity.